The short answer
Confirm the valerian species before combining this root product with daridorexant. If it is Valeriana officinalis, added drowsiness is a reasonable concern; the generic name alone does not establish that identity.
What this answer covers
Generic root/rhizome name does not confirm Valeriana officinalis.
- Supplement or preparation
- Radix et Rhizoma Valerianae
- Medication ingredient
- daridorexant
Why alertness matters
Daridorexant can impair alertness and next-day activities. Its label warns about additive effects with other central nervous system depressants. That precaution does not provide an adverse-event rate for this supplement combination.
What is known about this product
Valeriana officinalis guidance cautions about combining sedating substances, but the current root name does not identify that species.
Keep the evidence within its limits
Products differ in dose, composition and release. A study that fails to show better sleep does not prove that a product cannot impair alertness. Evidence about one extract does not establish the effects of every preparation.
Plan co-use with the prescriber
Discuss the exact product and other sleep medicines before adding it. A short spacing interval has not been shown to prevent additive impairment. Do not drive while impaired. If sleepwalking, sleep-driving or other activities while not fully awake occur, stop daridorexant and contact the prescriber promptly, as its label instructs.
Evidence and practical considerations
Side effects & toxicity
Unconfirmed generic valerian identity prevents validation of the original claim with V.officinalis evidence. A separate confirmed-species precaution is retained.
- Exact scope
- Generic root/rhizome name does not confirm Valeriana officinalis. with Daridorexant2591497 IN; oral QUVIVIQ hydrochloride tablets.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed daridorexant
Avoid strong CYP3A4 inhibitors and moderate/strong inducers; moderate inhibitors limit dose25mg. CNS-depressant effects and next-day impairment, complex sleep behaviors.
How this applies: Exact daridorexant RxCUI 2591497 IN, with stated salt/formulation/route bridge.
No exact botanical extract PK trial or supplement-combination incidence; distinguish modeled strong-modifier effects from measured clinical data.
Source 2: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Possible but unproven sleep-inducing effects; advises against combining valerian with alcohol or sedatives.
How this applies: Original source interpreted for daridorexant only within the stated preparation and endpoint limits.
Not a direct daridorexant combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 3: federal botanical identity and safety guidance
ods.od.nih.gov · Source check Sep 10, 2026
Population: Users of Valeriana officinalis.
The fact sheet covers only V. officinalis among more than 250 valerian species; possible additive sedation is theoretical.
How this applies: Original source interpreted for daridorexant only within the stated preparation and endpoint limits.
Not a direct daridorexant combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 4: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 391 participants with anxiety and insomnia.
Neither botanical improved its primary anxiety/insomnia outcome over placebo.
How this applies: Original source interpreted for daridorexant only within the stated preparation and endpoint limits.
Four-week kava/valerian insomnia/anxiety efficacy trial; failure to show benefit is not proof of absent sedation. No daridorexant combination.
Research assessment: · Open full citations ↗
Side effects & toxicity
If the product is confirmed as Valeriana officinalis, additive drowsiness with daridorexant is a conditional concern.
- Exact scope
- Confirmed Valeriana officinalis root product. with Daridorexant2591497 IN; oral QUVIVIQ hydrochloride tablets.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- Generic identity remains unresolved; no exact-pair rate or protective spacing.
Factors that may matter: Species; Dose; Other sedatives.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed daridorexant
Avoid strong CYP3A4 inhibitors and moderate/strong inducers; moderate inhibitors limit dose25mg. CNS-depressant effects and next-day impairment, complex sleep behaviors.
How this applies: Exact daridorexant RxCUI 2591497 IN, with stated salt/formulation/route bridge.
No exact botanical extract PK trial or supplement-combination incidence; distinguish modeled strong-modifier effects from measured clinical data.
Source 2: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Possible but unproven sleep-inducing effects; advises against combining valerian with alcohol or sedatives.
How this applies: Original source interpreted for daridorexant only within the stated preparation and endpoint limits.
Not a direct daridorexant combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 3: federal botanical identity and safety guidance
ods.od.nih.gov · Source check Sep 10, 2026
Population: Users of Valeriana officinalis.
The fact sheet covers only V. officinalis among more than 250 valerian species; possible additive sedation is theoretical.
How this applies: Original source interpreted for daridorexant only within the stated preparation and endpoint limits.
Not a direct daridorexant combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 4: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 391 participants with anxiety and insomnia.
Neither botanical improved its primary anxiety/insomnia outcome over placebo.
How this applies: Original source interpreted for daridorexant only within the stated preparation and endpoint limits.
Four-week kava/valerian insomnia/anxiety efficacy trial; failure to show benefit is not proof of absent sedation. No daridorexant combination.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Prepared exact daridorexant article with formulation-specific evidence and uncertainty. |
Article revision: 3d3e37562931c05d
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.